Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis

References

• Tampa M, Mitran CI, Mitran MI, et al. A new horizon for atopic dermatitis treatments: JAK inhibitors. J Pers Med. 2023 Feb 22;13(3):384. doi: 10.3390/jpm13030384. PMID: 36983565; PMCID: PMC10056980.
   PubMed Web of Science ®Google Scholar
• Ertus C, Scailteux LM, Lescoat A, et al. Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis. Br J Dermatol. 2023 Sep 15;189(4):368–380. doi: 10.1093/bjd/ljad229. PMID: 37410552.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020 Aug;183(2):242–255. doi: 10.1111/bjd.18898. Epub 2020 Mar 5. PMID: 31995838.
   PubMed Web of Science ®Google Scholar
• Reich K, DeLozier AM, Nunes FP, et al. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J DermatolTreat. 2022 May;33(3):1521–1530. doi: 10.1080/09546634.2020.1839008. Epub 2020 Nov 22. PMID: 33222559.
   Google Scholar
• Wollenberg A, Lio P, Kleyn E, et al. Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five phase III clinical trials. Eur J Dermatol. 2022 Jul 1;32(4):522–529. doi: 10.1684/ejd.2022.4280. English PMID: 36301752.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, Wollenberg A, et al. Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials. JAMA Dermatol. 2021 Jun 1;157(6):691–699. doi: 10.1001/jamadermatol.2021.1273. PMID: 33978711; PMCID: PMC8117062.
   PubMed Web of Science ®Google Scholar
• Thyssen JP, Werfel T, Barbarot S, et al. Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial. J DermatolTreat. 2023 Dec;34(1):2190430. doi: 10.1080/09546634.2023.2190430. PMID: 36912484.
   Google Scholar
• Reich K, Simpson E, Wollenberg A, et al. Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. Br J Dermatol. 2023 Feb 10;188(2):208–217. doi: 10.1093/bjd/ljac057. PMID: 36763879.
   PubMed Web of Science ®Google Scholar
• Bieber T, Reich K, Paul C, et al. BREEZE-AD4 study group. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). Br J Dermatol. 2022 Sep;187(3):338–352. doi: 10.1111/bjd.21630. Epub 2022 Jul 20. PMID: 35484697.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Forman S, Silverberg JI, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol. 2021 Jul;85(1):62–70. doi: 10.1016/j.jaad.2021.02.028. Epub 2021 Feb 16. PMID: 33600915.
   PubMed Web of Science ®Google Scholar
• Rosmarin D, Fretzin S, Strowd L, et al. Rapid improvement in skin pain severity and its impact on quality of life in adult patients with moderate-to-severe atopic dermatitis from a Double-blind, placebo-controlled baricitinib phase 3 study. J Cutan Med Surg. 2022 Jul;26(4):377–385. doi: 10.1177/12034754221088542. Epub 2022 Mar 31. PMID: 35354410.
   PubMed Web of Science ®Google Scholar
• Rosmarin D, Casillas M, Chen S, et al. Onset of symptom relief reported in daily diaries of patients with atopic dermatitis treated with baricitinib in a United States clinical trial (BREEZE-AD5). J Cutan Med Surg. 2022 May;26(3):262–266. doi: 10.1177/12034754211073661. Epub 2022 Jan 28. PMID: 35086348.
   PubMed Web of Science ®Google Scholar
• Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020 Dec 1;156(12):1333–1343. doi: 10.1001/jamadermatol.2020.3260. PMID: 33001140; PMCID: PMC7527941.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Nakahara T, Maari C, et al. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 phase 3 randomized trial. J Eur Acad Dermatol Venereol. 2021 Jul;35(7):1543–1552. doi: 10.1111/jdv.17278. Epub 2021 Jun 5. PMID: 33834521; PMCID: PMC8251919.
   PubMed Web of Science ®Google Scholar
• Torrelo A, Rewerska B, Galimberti M, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023 Jul 7;189(1):23–32. doi: 10.1093/bjd/ljad096. PMID: 36999560.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Bieber T, Alten R, et al. Baricitinib safety for events of special interest in populations at risk: analysis from randomised trial data across rheumatologic and dermatologic indications. Adv Ther. 2023 Apr;40(4):1867–1883. doi:10.1007/s12325-023-02445-w. Epub 2023 Feb 20. PMID: 36802049; PMCID: PMC9939375.
   PubMedGoogle Scholar
• Lexi-Drugs/baricitinib [Internet]. Waltham MA: UpToDate, Inc.; 2023. [cited 2023 Nov 11]. Available from: https://online.lexi.com/lco/action/home
   Google Scholar